Clinical Trials Directory
We are doing this study to find out if an experimental drug called ASP2138 (the study drug) is a safe and effective option for people who have pancreatic cancer that can be treated with surgery. We want to know if the study drug has a benefit when it is taken by patients before their surgery who then have standard chemotherapy after their surgery.
We are doing this study to compare 2 different options for preventing strokes for people who have atrial fibrillation. We want to find out if apixaban or aspirin is the better choice to help prevent future strokes for patients with atrial fibrillation and who had a recent brain hemorrhage.
If you join this study, you will receive a medicine called ASP546C through a vein every three weeks. You will also give blood and urine samples so doctors can check your health and how your body responds to the treatment. During the study, you will have regular scans such as CT or MRI to see how your cancer is changing.
This study has three parts: - Screening (up to 21 days): You'll get health checks like heart tests, scans, and blood work. - Study Drug Period (28-day cycles): You'll be randomly placed in one of two groups: - One group gets AZD3632 alone. -The other gets AZD3632 with another medicine called posaconazole. You'll have regular visits for tests and questions. - After Treatment: You'll have a safety check 30 days after your last dose, then visits every 12 weeks to see how your disease is doing.
In this study, people are placed into one of two groups based on certain features found in their genes. The first group, called Cohort 1, includes people who have low‑risk genetic signs. To be in this group, a person must have a mutated IGHV gene, must not have a 17p deletion, and must not have a TP53 mutation. All three conditions must be true. People in this group will first take a medicine called acalabrutinib for two cycles. After that, they will take a combination of acalabrutinib and venetoclax, called AV, for twelve more cycles. The second group, called Cohort 2, includes people who have any high‑risk genetic signs. This may include having an unmutated IGHV gene, a 17p deletion, a TP53 mutation, or a mix of these.
We are doing this study to find out if an experimental drug called ataciguant (the study drug) is an effective option to slow the rate of calcium deposits in the aortic valve for people who have aortic stenosis.
If you join this study, you will have a procedure where the study medicine is placed into the back of your eye. After this, you will return for follow up visits for up to five years so doctors can check how your eyes are doing. There will be about seventeen visits in total. At these visits, doctors will test your vision and examine your eyes to watch for changes and make sure the treatment is safe.
This study is testing a new medicine called MYK-224 to help people with a heart problem called HFpEF. That means their heart pumps well but does not relax properly. People in the study also have signs that their heart is not working normally. The study has four groups, called cohorts. Duke is only helping with Cohort 4, which will include about 160 people. These people will be split into four smaller groups. Three groups will get different amounts of the real medicine, and one group will get a fake medicine called a placebo. The treatment will last 20 weeks. A special team of doctors will check to make sure the medicine is safe and decide how much each group should get. To join the study, people must meet certain health rules.